@ImmunoFrontier was named by combining gimmuno-g for immunity and
@Chemotherapeutic drugs based on cell toxicity have been playing a major role
in cancer therapeutic drugs. However the development of an innovative and
effective drug with low side effect based on a new mechanism has been
yearned for a long time. And this hope is now becoming to be realized in
this century after having innovation in medical biologics in 1990s. One of
these new cancer therapies is cancer immunotherapy. Although it has been
well known that cancer immunotherapeutic drugs are very safe comparing to
chemotherapeutic or molecular target drugs, the development of
immunotherapeutic drugs has not been successful because of the difficulty in
proving efficacy of immunotherapeutic drugs. However the concept of cancer
immunotherapy has been proven with high efficacy of antibodies recent
@Now the development of cancer vaccines as the next generation of cancer
immunotherapy after antibodies has been conducted actively mainly in the US
and Europe. Cancer vaccines have three unique characteristics not to be seen
in other therapeutic drugs, which are searching for tumor cells (specificity
of immunity), damaging/removing tumor cells (cytotoxicity by killer T
cells), and are sustaining anti-tumor activity (memory of immunity).
@ImmunoFrontier will go forward the development of cancer therapeutic drugs
which can suppress tumor growth, recurrence and metastasis for a long period
with our unique and advanced technology, CHP-cancer vaccines, to meet the
expectations of many patients and their families longing for a new
therapeutic drug, our shareholders, and society.
|President and CEO Tadashi Hishida, Ph.D.